Syneron Medical Ltd.
http://www.syneron.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Syneron Medical Ltd.
Deal Watch: Gilead Acquires Xilio’s IL-12 Activating Candidate
Plus deals involving Avalo/AlmataBio, AbbVie/Parvus, NovaBay/Eyenovia, Bayer/Aignostics, Merck & Co./Pearl, tech transfer agreements and deals in brief.
Tech Transfer Roundup: MD Anderson, Replay Found Allogeneic TCR-NK Cell Therapy Play Syena
Start-up hopes to bring its first candidate, an NY-ESO-1-targeting off-the-shelf product, into the clinic in Q2. Astex and Cardiff University team up on novel therapies for neurodegenerative disease.
Nektar And PureTech Merger Talks Terminated
The UK’s PureTech and US biotech Nektar have ended discussions about a potential merger which analysts did not see coming, but a deal could still happen and other companies may also make a move.
ESMO: Cardiff Oncology Falls Despite Onvansertib’s Broad Potential In KRAS-Mutant CRC
A planned Phase II trial for PLK1 inhibitor onvansertib in KRAS-mutant colorectal cancer may support accelerated approval, but results are two years off and the company cut its prostate cancer plans to conserve cash.
Company Information
- Industry
- Medical Devices
-
Pharmaceuticals
- Drug Delivery
-
Medical Devices
- Consumables, Central Supplies
- Implantable Devices
- Infection Control-Sterilization
- Infusion Therapy Equipment and Supplies
- Laser
- Monitoring Equipment & Devices
- Radiofrequency Devices
- Rehabilitation Equipment and Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
-
- Inlight Corp
- Syneron China
- Candela Corporation
- Ultrashape
- TransPharma
- New Star Lasers, Inc.
- CoolTouch, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice